Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of Uro-Vaxom for uncomplicated recurrent urinary tract infections
2008-001784-11Phase 2Terminated
- Sponsor
- Alita Pharmaceuticals
- Start
- Jun 2008
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of OM-89 in urinary tract infection (UTI) (3 arms), sponsored by Alita Pharmaceuticals. Primary endpoint: Time to first recurrence of a qualifying urinary tract infection. Started Jun 2008; status: terminated.
02
Drugs
OM-89
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on 2008-001784-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001784-11.